Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR1313)
Drug Name
Pomalidomide
Synonyms
Pomalidomide; Pomalidomide (CC-4047); Pomalyst; Actimid; IMID-3; Imnovid; 19171-19-8; 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-; 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide; 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione; 4-Aminothalidomide; 4-amino-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione; 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione; 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; AK104087; CC 4047; CC-4047; CHEBI:72690
Indication Breast cancer [ICD11: 2C60] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 273.24 Topological Polar Surface Area 110
Heavy Atom Count 20 Rotatable Bond Count 1
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 5
Cross-matching ID
PubChem CID
134780
PubChem SID
10243744 ; 14848461 ; 29312424 ; 50086901 ; 50447747 ; 53787052 ; 57345004 ; 96025659 ; 103100612 ; 103221733 ; 104253216 ; 104382952 ; 117621779 ; 124757341 ; 125164145 ; 125697093 ; 129427476 ; 135089995 ; 135727444 ; 136348254 ; 136367549 ; 136946644 ; 137009922 ; 142523166 ; 143499180 ; 149539643 ; 152235120 ; 152258286 ; 152343904 ; 160647125 ; 160837107 ; 162011791 ; 162012270 ; 162037668 ; 162189531 ; 162856472 ; 163398415 ; 163778934 ; 163907985 ; 164194051 ; 172889447 ; 172889448 ; 173130995 ; 174007398 ; 174528127 ; 175424471 ; 175427148 ; 178103920 ; 179116970 ; 186007045
ChEBI ID
ChEBI:72690
CAS Number
19171-19-8
TTD Drug ID
D0A3ZU
Formula
C13H11N3O4
Canonical SMILES
C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
InChI
1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)
InChIKey
UVSMNLNDYGZFPF-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
5-hydroxypomalidomide DM002882
72736581
Oxidation - Hydroxylation 1 [4] , [3] , [5]
7-hydroxypomalidomide DM002884
86709849
Oxidation - Hydroxylation 1 [4] , [3] , [5]
Pomalidomide metabolite M10 DM002885
22612842
Unclear 1 [4]
Pomalidomide metabolite M18 DM002887
21988622
Unclear 1 [4]
Pomalidomide metabolite M19 DM002886
9922018
Oxidation - Hydroxylation 1 [4] , [3]
Pomalidomide metabolite M2 DM002888
79490
Unclear 1 [4]
5-hydroxypomalidomide glucuronide DM002883 N. A. Conjugation - Glucuronidation 2 [4] , [3] , [5]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR002076 Pomalidomide 5-hydroxypomalidomide Oxidation - Hydroxylation CYP1A2 ... [4], [3], [5]
MR002077 Pomalidomide 7-hydroxypomalidomide Oxidation - Hydroxylation CYP1A2 ... [4], [3], [5]
MR002078 Pomalidomide Pomalidomide metabolite M10 Unclear Unclear [4]
MR002079 Pomalidomide Pomalidomide metabolite M19 Oxidation - Hydroxylation CYP1A2 ... [4], [3]
MR002080 Pomalidomide Pomalidomide metabolite M18 Unclear Unclear [4]
MR002081 Pomalidomide Pomalidomide metabolite M2 Unclear Unclear [4]
MR002075 5-hydroxypomalidomide 5-hydroxypomalidomide glucuronide Conjugation - Glucuronidation Unclear [4], [3], [5]
⏷ Show the Full List of 7 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 1A2 (CYP1A2) DME0003 Homo sapiens
CP1A2_HUMAN
1.14.14.1
[2]
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[2]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[3]
Mephenytoin 4-hydroxylase (CYP2C19) DME0021 Homo sapiens
CP2CJ_HUMAN
1.14.14.1
[2]
References
1 Pomalidomide was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Population pharmacokinetics of pomalidomide. J Clin Pharmacol. 2015 May;55(5):563-72.
3 Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects. J Clin Pharmacol. 2015 Feb;55(2):168-78.
4 Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration Cancer Chemother Pharmacol. 2013 Feb;71(2):489-501. doi: 10.1007/s00280-012-2040-6.
5 Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice Xenobiotica. 2017 Oct;47(10):844-848. doi: 10.1080/00498254.2016.1247218.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.